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Abstract 
Background: Treatment with TNF inhibitors is very efficient in the majority of the patients with rheumatoid arthritis 
(RA), but it does not achieve a sufficient treatment response in 40–50% of the cases. Goal of the study was to assess 
functional ex vivo-tests of RA monocytes as prognostic parameters of the subsequent treatment response.
Methods: 20 anti-TNF naïve RA patients were enrolled in a prospective, open-label trial, and Etanercept therapy was 
initiated. Prior to treatment, reverse signaling was induced in peripheral blood monocytes by tmTNF crosslinking via 
TNFR2:Ig construct Etanercept in a standardized ex vivo-assay. Released cytokine and cytokine receptor concentra-
tions were determined as parameters of the monocyte response.
Results: Crosslinking of tmTNF and consecutive reverse signaling led to production of pro- and anti-inflammatory 
cytokines and of soluble cytokine decoy receptors such as sTNFR1 and sIL-1R2. Several of the measured concentra-
tions were found to correlate with the treatment response according to the EULAR criteria. The correlation was most 
pronounced in sTNFR1 concentrations (r = −0.657, p = 0.0031), which also predicted a good clinical response with 
the highest sensitivity and specificity according to EULAR criteria.
Conclusions: Herein we propose that the tmTNF crosslinking-triggered shedding of soluble decoy receptors 
and production of anti-inflammatory cytokines could contribute to the clinical efficacy of TNF inhibitors, and that 
in vitro quantification of this secretion by RA monocytes prior to treatment can be used to predict the clinical 
response. Further development of such standardized tests could be a step towards personalized medicine by provid-
ing rheumatologists with a rational choice for first line biological therapy in patients with RA.
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Background
The clinical efficacy of specific cytokine inhibitors in 
rheumatoid arthritis (RA) reveals the pivotal role of pre-
dominantly monocytic cytokines like IL-1β, TNF or IL-6 
in the pathogenesis of the disease. The relevance of the 
circulating monocyte pool is highlighted by several path-
ological subpopulations including CD14bright CD16+ as 
well as CD14bright CD56+ cells [1, 2]. In addition to those 
pathological subpopulations, the global monocyte pool in 
RA is characterized by increased cell surface expression 
of transmembrane TNF (tmTNF), which is not detectable 
in healthy controls [3].
We and others have extensively investigated the cellular 
signaling pathways initiated by tmTNF ligation with solu-
ble tmTNF ligands like anti-TNF antibodies or TNFR2:Ig 
construct Etanercept [3–7]. This so-called reverse signal-
ing inhibits the intrinsic NFkappaB activation and IL-1β 
secretion characteristic for RA monocytes, and induces 
apoptosis [3]. Contrary to expectations, the rate of apop-
tosis induced by reverse signaling is not related to the 
therapeutic efficacy of TNF inhibitors [8].
Open Access
*Correspondence:  ulf.wagner@medizin.uni-leipzig.de 
†Undine Meusch and Marco Krasselt contributed equally to this work 
‡Maria Klingner and Ulf Wagner contributed equally to this work
Rheumatology Unit, Department of Internal Medicine, University 
of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany
Page 2 of 9Meusch et al. J Transl Med  (2015) 13:256 
In Crohn’s disease, anti-TNF antibodies are also bind-
ing to tmTNF positive myelomonocytic cells [9]. Patients 
with high numbers of tmTNF+ immune cells have higher 
response rates to anti-TNF treatment due to higher rate 
of apoptosis [10], which is in contrast to our findings in 
patients with RA.
In RA, tmTNF ligation by soluble anti-TNF antibod-
ies induces not only apoptosis, but also shedding of the 
soluble cytokine decoy receptors IL-1sRI and IL-1sRII. 
Secretion levels of IL-1sRII in vitro are linked to a good 
response to anti-TNF blockade [8]. This production is 
significantly enhanced when tmTNF molecules are not 
merely ligated by a soluble ligand, but are cross-linked by 
surface immobilized antibodies [7]. Importantly, in such 
scenario, induction of apoptosis does not occur.
To investigate the response of RA monocytes to such 
tmTNF crosslinking by a ligating molecule immobilized 
on plastic or cell surfaces, a standardized in vitro assay was 
established. Goal of the study was to investigate tmTNF 
crosslinking-induced cytokine production as a poten-
tial prognostic parameter for the therapeutic response 
to Etanercept. The results show that the crosslinking-
induced concentrations of anti-inflammatory cytokines 
and soluble decoy receptors can distinguish responders 
from non-responders prior to initiation of therapy.
Methods
Patients and study design
Details of study design, inclusion criteria, and clinical 
documentation performed have been reported previously 
[8]. The design of the clinical study has been approved 
by the ethics committee of the University of Leipzig, and 
informed consent was obtained from each patient before 
enrolment into the study. A total of 33 consecutive, anti-
TNF naïve patients with RA according to the revised cri-
teria of the American College of Rheumatology (ACR) 
[11], who were assessed by their rheumatologists to 
require treatment with Etanercept based on their clinical 
status, were screened for the study. 13 of them could not 
be initiated on anti-TNF treatment due to subsequently 
discovered various contraindications, newly diagnosed 
co-morbidities, requirement of surgery or withdrawal of 
patient’s consent. In 20 patients, Etanercept treatment 
was started.
At baseline, 80% (16 patients) were treated with con-
ventional DMARDs, given either as monotherapy or in 
combination, and 20% received glucocorticoids only. All 
patients were treated with non-steroidal anti-inflamma-
tory drugs (NSAIDs) for symptomatic relief. During the 
study, two patients withdrew their consents before effi-
cacy could be assessed.
In the final cohort of 18 patients, mean age was 
53 years, and the mean disease duration was 4 years: 65% 
of the patients were RF IgM-seropositive, and 80% had 
anti-CCP antibodies. None of the patients showed any 
clinical sign of an infection at baseline visit.
Blood samples for monocyte isolation were taken 
at baseline, week 4, week 12 and week 24. Each visit 
included a physical examination, routine laboratory tests 
and assessment of the patient’s global health in order to 
determine the current disease activity (Disease Activity 
Score 28 joints, DAS28). The mean DAS28 of all patients 
before initiating treatment was 4.69, at week 4 3.51, at 
week 12 3.17 and after 24 weeks of therapy 2.84.
After 4 weeks of therapy, 80% of the patients reached a 
response as defined by EULAR [12] with 31.25% achiev-
ing a good clinical response and 68.75% achieving a mod-
erate response. Response rates increased during the study 
and reached a good response in 56.25% of all responders 
after 6 months of treatment.
A good response according to EULAR is defined as an 
improvement in DAS28 >1.2 (present DAS28 ≤3.2), a 
moderate response as an improvement between 0.6 and 
1.2 (present DAS28 ≤5.1) or >1.2 (present DAS28 >3.2). 
Improvements ≤0.6 or between 0.6 and 1.2 (present 
DAS28 >5.1) are considered as no response.
Monocyte isolation, cell culture and stimulation
Monocytes from peripheral blood were separated as pre-
viously described [7]. 2 × 105 monocytes per 200 µl were 
incubated in RPMI 1640 supplemented with 5% human 
AB serum (heat-inactivated). Stimulation of cells was car-
ried out either with 100 µg/ml rituximab (Roche, Basel, 
Switzerland) as an IgG control or with TNFR2:Ig con-
struct Etanercept (100 µg/ml, Pfizer, New York, NY, USA) 
for 16 h, either as a soluble or a plate-bound molecule, as 
indicated for individual experiments.
Flow cytometry
After separating monocytes, cells were stained with flu-
orescence-bound antibodies for CD14, TNFR1, TNFR2 
and CD54 (R&D Systems, Minneapolis, MN, USA) and 
analyzed on a FACSCalibur system.
Cytokine detection
Cytokine levels in cell culture supernatants were meas-
ured with cytometric bead arrays (CBA) or enzyme-
linked immunosorbent assay (ELISA) technique (BD 
biosciences, Franklin Lakes, NJ, USA) according to the 
manufacturer’s protocol.
Statistics
All analyses were conducted using GraphPad PRISM Ver-
sion 6 (GraphPad Software Inc., San Diego, CA, USA). 
Normality test was performed prior to all comparisons. 
To assess statistical significance, Student’s t test was used 
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on normal distributions. Otherwise, Mann–Whitney 
rank sum test was performed. A statistical difference was 
considered when the p value was less than 0.05.
Correlation between two parameters was analyzed with 
either Pearson’s product–moment correlation (for nor-
mally distributed data) or Spearman (for data not nor-
mally distributed).
Results
Increased frequencies of TNFR1+ monocytes 
and decreased monocytic CD54 expression are associated 
with a good therapeutic response to TNF inhibition
We found a significant correlation between the mean 
expression of Intercellular Adhesion Molecule 1 (ICAM-
1, CD54) and the DAS28 response (ΔDAS28) at week 
12, and significantly lower values in EULAR responders 
(Fig. 1a, b, representative histograms in Fig. 1c). The fre-
quency of monocytes positive for CD54, however, did not 
differ between responders and non-responders (data not 
shown). In addition, the mean level of TNFR1 expression 
on monocytes correlated significantly with the DAS28 
response after 12 weeks (r = −0.4907, p = 0.028, Fig. 1d) 
and after 6 months (r = −0.46, p = 0.041, Fig. 1e, repre-
sentative histograms in Fig. 1f ). No such correlation was 
observed for TNFR2 expression (data not shown).
Cytokine decoy receptor levels induced by tmTNF 
crosslinking predict subsequent responses to anti‑TNF 
therapy
In vivo, the effects of the pro-inflammatory monocytic 
cytokines TNF and IL-1β are counterbalanced by soluble 
cytokine decoy receptors released from the cell surface 










































































Fig. 1 Monocytic surface expression of TNFR1 and CD54 are linked to anti-TNF treatment response. a Scatterplot showing the correlation of CD54 
expression on ex vivo separated RA-monocytes with the decrease in the patients’ DAS28 (ΔDAS28) after 12 weeks (n = 18). Receptor expression is 
given as mean fluorescence intensity as determined by FACS. b Bar graph depicts mean and SEM of CD54 expression (mean fluorescence) in the 
study cohort on monocytes in patients with a good EULAR response (mean 62.1 ± 8.4) and non-responders (mean 83.48 ± 3.99), respectively. c 
Cell surface expression of CD54 was determined by flow cytometry on freshly isolated monocytes. Shown are representative histograms from one 
patient with a good response (light grey curve) and from a non-responder (dark grey curve) in comparison to the isotype controls (white curve; dark 
grey line for non-responder, light grey line for good responder). d, e Scatterplot showing the correlation between TNFR1 expression determined 
ex vivo on RA monocytes and the decrease in DAS28 (ΔDAS28) after 12 weeks (n = 17) (d) and 24 weeks (n = 18) (e). TNFR1 expression was deter-
mined by mean fluorescence intensity. f Cell surface expression of TNFR1 on freshly isolated monocytes. Shown are representative histograms from 
one patient with a good response (dark grey filled curve) and from a non-responder (light grey filled curve) in comparison to the isotype controls (dark 
grey line for good responder, light grey line for non-responder). Non-responders are defined as patients achieving only a moderate or no response. 
DAS28, disease activity score 28.
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by shedding. tmTNF crosslinking with the TNFR2:Ig 
construct Etanercept was found to induce the release of 
several cytokine decoy receptors in RA monocytes. The 
tmTNF crosslinking-induced concentrations of sTNFR1, 
sIL-1R1 and sIL-1R2 at baseline were all found to corre-
late with the DAS28 response after 4 weeks of observa-
tion (Fig. 2a–c). The strongest correlation with ΔDAS28 
was found in sTNFR1 (r = −0.657, p = 0.0031). tmTNF 
crosslinking-induced shedding of the decoy receptors 
was significantly higher in patients with a good EULAR 
response than in those with moderate or no response 
(Fig. 2d–f). In contrast to the effects of tmTNF crosslink-
ing with the TNFR2:Ig construct Etanercept, crosslink-
ing with therapeutic anti-TNF antibodies did not induce 
cytokine responses (data not shown).
Secretion of cytokines induced by tmTNF reverse 
signaling and crosslinking is predictive of the subsequent 
therapeutic response
Transmembrane TNF crosslinking in vitro for 16 h trig-
gered the production of several cytokines, while incu-
bation with a plate-bound irrelevant control antibody 
induced only significantly lower concentration (Fig.  3a). 
The tmTNF crosslinking-induced secretion of TNF was 
significantly higher in patients who achieved a good 
EULAR response after 4 weeks of treatment (Fig. 3b).
Secretion levels of IL-8, when triggered only by incuba-
tion with soluble tmTNF ligand, were also found to cor-
relate with the ΔDAS28 response observed after 4 weeks 
of therapy (r = −0.6155, p = 0.0039, Fig. 3c). Moreover, 
monocytes from patients achieving good or moderate 
responses according to the EULAR criteria responded 
with significantly higher IL-8 secretion upon crosslink-
ing-independent reverse signaling at baseline than mono-
cytes from non-responders (Fig. 3d).
Longitudinal analysis of tmTNF crosslinking induced 
cytokine secretion revealed a significant reduction in the 
concentrations of TNF (p < 0.0001) and IL-8 (p = 0.0311) 
in the supernatant, but no difference in any of the other 
cytokines or soluble receptors analyzed (data not shown).
Secretion of IL‑10 induced by tmTNF crosslinking in RA 
monocytes predicts the subsequent therapeutic response
Concentrations of the anti-inflammatory cytokine IL-10 
induced by tmTNF crosslinking were also found to corre-
late with the DAS28 response after 4 weeks (r = −0.4803, 
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Fig. 2 tmTNF crosslinking-induced cytokine decoy receptor levels are associated with a good response to anti-TNF treatment. a–c Scatterplots 
depict the correlation of tmTNF crosslinking induced monocytic secretion of sTNFR1 (a), sIL-1R1 (b) and sIL-1R2 (c) with the decrease in the patients’ 
DAS28 (ΔDAS28) after 4 weeks of anti-TNF therapy. Each dot represents one patient (n = 18). d–f Box plots depict the concentrations of the tmTNF 
crosslinking-induced cytokine decoy receptors sTNFR1 (d), sIL-1R1 (e) and sIL-1R2 (f) in patients with a good response according to the EULAR 
response criteria (responder, light grey bars, n = 4) compared to patients achieving only a moderate or no response (non-responder, dark grey bars, 
n = 14). Levels of significance as indicated.
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p  =  0.0436, Fig.  4a) and to be higher in patients with 
a good EULAR response after 4  weeks of treatment 
(Fig. 4b).
In order to investigate a possible link between IL-10 
and disease activity in  vivo, we determined serum con-
centrations of the cytokine at baseline and found them 
to be significantly related to disease activity at baseline 
(Fig. 4c) and week 12 (Fig. 4d). This correlation was lost 
later on in the longitudinal analysis during the 6 months 
of follow-up under anti-TNF therapy. Interestingly, we 
also found that patients under anti-TNF treatment show 
a continuous increase of serum concentration of IL-10 
(Fig. 4e), which might contribute to clinical efficacy of the 
treatment.
Receiver operating characteristic (ROC) analysis of tmTNF 
crosslinking‑induced parameters
Receiver operating characteristic curve analysis was 
performed in order to assess the accuracy of tmTNF 
crosslinking-induced cytokines and cytokine decoy 
receptors as biomarkers for predicting the subsequent 
TNF inhibitor response. The tmTNF crosslinking-
induced concentrations of IL-10, sIL1R1 and TNFR1 
were all found to predict with significance the response 
to anti-TNF therapy. The area under the curve (AUC) was 
0.9107 (95% confidence interval 0.738–1.084, p = 0.015) 
for IL-10, 0.9286 (95% confidence interval 0.8404–1.053, 
p =  0.0108) for sIL1R1 and 1.000 (95% CI 1.000–1.000; 
p =  0.0029) for sTNFR1. Accordingly, sTNFR1 was the 
biomarker with the best predictive value. The analysis 
identified a cut-off point of 484 pg/ml as an optimum for 
sTNFR1 to differentiate between patients with high and 
low tmTNF crosslinking-induced sTNFR1 secretion, with 
a sensitivity as well as specificity of 100% for the predic-
tion of response to anti-TNF therapy. All determined cut-
off values and the resulting sensitivity and specificity for 
the three crosslinking-induced parameters are given in 
detail in Fig. 5.
Discussion
Circulating RA monocytes are known to be a heteroge-
neous cell population containing pathological subpopu-
lations prone to exaggerated inflammatory responses. 
We report here an association of increased expression 
of ICAM-1 on monocytes with a less favorable response 
to TNF inhibition, which would imply them in the per-
petuation of the autoimmune disease. The potential 































































Fig. 3 Reverse signaling and tmTNF crosslinking-induced cytokine secretion is higher in responders to TNF inhibitors. a Bar graph shows concentra-
tions of tmTNF crosslinking-induced secretion of the indicated cytokines (black bars) and concentrations found in control cultures containing an 
irrelevant, plate-bound antibody (grey bars, n = 18). Levels of significance: *p < 0.05, **p < 0.01, ***p < 0.001. b Box plots depict the concentrations 
of the tmTNF crosslinking-induced TNF secretion in patients with a good response according to the EULAR response criteria (responder, n = 4) 
compared to patients achieving only a moderate or no response (non-responder, n = 14). c Scatterplot depicts correlation of concentrations of 
reverse signaling-induced IL-8 with the decrease in DAS28 (ΔDAS28) after 4 weeks of therapy. IL-8 was measured by ELISA (n = 18). d Bar graph 
depicts reverse signaling-induced IL-8 concentrations in patients with any EULAR response (grey bar, n = 15) compared to those with no response 
at all (black bar, n = 3) at the given time points. Levels of significance: *p < 0.05, **p < 0.01, ***p < 0.001.
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increased migratory potential, therefore, which facilitates 
entry into the rheumatoid synovium.
In contrast, increased frequencies of TNFR1 expressing 
monocytes were found to be associated with a more pro-
nounced decrease in disease activity and a better thera-
peutic response. One possible explanation could be, that 
increased surface expression of TNFR1 on monocytes 
is accompanied by higher concentrations of sTNFR1, 
which are available as decoy receptor in vivo, and which 
are released due to shedding of the receptor. Alterna-
tively, increased surface expression of TNFR1 could 
lead to higher rates of apoptosis among pro-inflamma-
tory monocytes due to TNFR1-TRADD signaling [13], 
but further studies—including the investigation of the 
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Fig. 4 tmTNF crosslinking-induced IL-10 secretion and serum IL-10 concentrations are associated with clinical response and disease activity, respec-
tively. a Scatterplot depicts correlation of tmTNF crosslinking-induced IL-10 with the decrease in DAS28 (ΔDAS28) after 4 weeks of therapy (n = 18). 
b Bar graph depicts tmTNF crosslinking-induced IL-10 concentrations in patients with a good EULAR response (responder, n = 4) compared to 
those with a moderate or no response (non-responder, n = 14) after 4 weeks of anti-TNF therapy. c, d Scatterplots showing the correlation of 
serum concentrations of IL-10 determined in RA patients at baseline (n = 18) with the disease activity (DAS28) at baseline (c) and after 12 weeks of 
anti-TNF therapy (d). e Longitudinally determined serum concentrations of IL-10 in RA patients under anti-TNF treatment. Levels of significance as 
indicated. BL baseline, W week.
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influence of expression and activity of TACE in this sce-
nario—are necessary to substantiate this.
TNFR1 plays a pivotal role in pro-inflammatory 
cytokine and chemokine secretion in RA [14]. The solu-
ble decoy receptor sTNFR1 has been suggested to act 
as a TNF activity attenuator due to competition with 
the remaining cell-bound receptors resulting in a neu-
tralization of TNF [15]. Indeed, knock-in mice with a 
non-sheddable TNFR1 mutant show an accelerated 
and more severe TNF-dependent chronic inflamma-
tory arthritis [16]. Accordingly, our observation of a 
better therapeutic outcome in patients with monocytes 
releasing high levels of sTNFR1 in response to tmTNF 
crosslinking can also be interpreted as evidence of a 
possible anti-inflammatory effect of the decoy receptor, 
provided that sTNFR1 is released in comparable concen-
trations in the rheumatoid synovium in vivo.
Similarly, the induction of high levels of the anti-
inflammatory cytokine IL-10 can also contribute to the 
therapeutic response if present in vivo. IL-10 production 
elicited by tmTNF reverse signaling has been reported 
previously [17] and interpreted as a potent anti-inflam-
matory response. In line with this hypothesis, we found 
increasing concentrations of IL-10 in sera of the patients 
under anti-TNF treatment, although this trend did not 
reach statistical significance. The significant association 
of IL-10 serum concentrations determined at baseline 
with the disease activity indicates, that up-regulation of 
this IL-10 secretion might indeed serve as an anti-inflam-
matory attenuator in the chronic autoimmune disease.
This confirms previous reports of anti-inflammatory 
effects of this cytokine in RA, which has been associated 
with less severe joint destruction [18, 19].
Concentrations of IL-8 have been reported to be ele-
vated in sera and synovial fluid from RA patients [20], 
and TNF blockade is able to decrease those levels [21]. 
Moreover, experimental injection of IL-8 in joints of 
rodents leads to synovial tissue damage due to neutrophil 
infiltration, mimicking RA [22]. Therefore, the increased 
production of IL-8 in monocytes from anti-TNF treat-
ment responders cannot readily be explained, and needs 
to be further investigated.
IL-1 is another monocytic cytokine involved in the 
inflammatory response in RA, and both soluble IL-1 
receptors, sIL-1R1 [23] and sIL-1R2 [24], have been 
shown to act as decoy receptors. In a previous study [8], 
we found a negative correlation with the DAS response 
for concentrations of sIL-1R2 induced by reverse signal-
ing without crosslinking, indicating that this pathway 
most likely does not contribute to therapeutic efficacy. 
In the data presented, the concentration of sIL-1R1 and 
sIL1-R2 elicited by tmTNF crosslinking-induced stimu-
lation of monocytes was found to correlate significantly 
with the decrease of disease activity after 4  weeks of 
therapy. Again, this could indicate an inhibitory effect of 
the soluble decoy receptor, which could also occur in vivo 
following administration of TNF inhibiting agents.
Conclusions
The most important result of the study is that produc-
tion of the soluble decoy receptors for both TNF and IL-1 








































































Fig. 5 ROC curve analysis for predicting the response to TNF 
inhibiting agents. The diagnostic accuracy [frequency (in %) of true 
positives = sensitivity and of false positives = 100% − specificity] 
is presented for the tmTNF crosslinking-induced concentrations of 
IL-10 (a), sIL-1R1 (b) and sTNFR1 (c). Each dot represents one patient 
(n = 18). Area under the curve (AUC), confidence intervals (95% 
CI) and level of significance are given for each analysis. Sensitivity, 
specificity and the determined cut-off values are calculated for the 
discrimination between patients with a good EULAR response (n = 4) 
and those with a moderate or no response (n = 14) after 4 weeks of 
therapy.
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appears to be up-regulated simultaneously in patients 
with a good response to TNF inhibitors. Accordingly, 
those inhibitors of the inflammatory response could 
be part of a counter-regulatory mechanism that is acti-
vated in RA patients and that can be amplified by tmTNF 
crosslinking.
We propose, therefore, that tmTNF crosslinking due to 
anti-TNF therapy activates the same anti-inflammatory 
program, and that the responsiveness of this mechanism 
in  vitro is a prognostic indicator of the efficacy of anti-
TNF treatment in vivo.
In conclusion, we have demonstrated, that functional 
in vitro responses elicited in peripheral blood monocytes 
from RA patients by tmTNF crosslinking can be used to 
predict the therapeutic efficacy of anti-TNF treatment 
in RA. Monocytic production of cytokines and cytokine 
decoy receptors in particular was able to predict the 
response according to the EULAR criteria with a clini-
cally meaningful sensitivity and specificity. The stand-
ardized ex vivo-analysis in patients prior to initiation of 
therapy could therefore be used as a diagnostic tool and 
provide clinically important prognostic information that 
can prevent primary treatment failures.
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